ArticleFrontiers in pharmacology2026
Sodium-glucose cotransporter 2 inhibitors and constipation: a two-sample mendelian randomization study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Evidence regarding the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibition on constipation is conflicting and the underlying mechanism unknown. We aimed to investigate the causal effect of SGLT-2 inhibition on constipation and the potential mediating role of circulating metabolites. Methods: We conducted a two-sample Mendelian randomization (MR) study. Genetic instruments for SGLT-2 inhibition were constructed from variants associated with SLC5A2 gene expression and glycated hemoglobin (HbA1c) levels. Summary-level data for constipation and 452 circulating metabolites were obtained from large-scale genome-wide association studies (GWAS). The primary analysis used the inverse-variance weighted method, supplemented by extensive sensitivity analyses. A two-step MR approach was applied to quantify mediation. Results: Genetically proxied SGLT-2 inhibition was associated with a reduced risk of constipation (OR 0.31, 95% CI 0.19-0.53, Conclusion: This study provides genetic support for a causal relationship between SGLT-2 inhibition and reduced constipation risk, and identifies DSGEGDFXAEGGGVR as a potential mediating metabolite. These findings offer insights into a possible pharmacological pathway that may inform future approaches to constipation management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.